An agenda for UK clinical pharmacology: Pharmacoepidemiology
Version of Record online: 8 MAY 2012
© 2012 The Author. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society
British Journal of Clinical Pharmacology
Special Issue: Agenda for Clinical Pharmacology Issue
Volume 73, Issue 6, pages 973–978, June 2012
How to Cite
Evans, S. J. W. (2012), An agenda for UK clinical pharmacology: Pharmacoepidemiology. British Journal of Clinical Pharmacology, 73: 973–978. doi: 10.1111/j.1365-2125.2012.04248.x
- Issue online: 8 MAY 2012
- Version of Record online: 8 MAY 2012
- Accepted manuscript online: 23 FEB 2012 05:12AM EST
- RECEIVED; 18 January 2012; ACCEPTED; 30 January 2012; ACCEPTED ARTICLE PUBLISHED ONLINE; 23 February 2012
Current concerns over the safety of medicines once they have been marketed mean that pharmacoepidemiology is of increasing importance. There are three main areas in which further research is needed.
1 To improve the methods used to make causal inference of effects of medicines and to raise the quality of the reporting and critical appraisal tools, so that the strengths and weaknesses of the new methods can be judged.
2 To apply the methods in areas where randomized trials cannot easily be done, such as in pregnancy.
3 To use electronic health records as fully as possible, using linkage between different databases, ensuring the data are of as high quality as possible.
Public health and public perceptions mean that much of pharmacoepidemiology must be done using non-industry funding sources.